Consider an illustrative vertical-farming business. The growing technology works and customers like the produce. Yet electricity, labour and occupancy costs exceed what the selling price can cover. More output does not by itself solve the gap.
An energy-price shock would expose that vulnerability. It would not, on its own, establish why a particular named company failed. The useful question is how sensitive the operating model is to a change in its largest costs.
A commercial-readiness review examines the next milestone. A risk review asks what could prevent the company from reaching it.
This article proposes five connected risks to examine in a food biotech business. It is an editorial framework, not the result of a documented census of company failures.
Some structural risks can be detected and reduced early. A review cannot make every external shock foreseeable or every failure preventable.
The assumption to test
The myth is that companies die from external shocks.
The funding market turned. Energy prices spiked. A competitor raised a monster round. Retail delisted the category. These are the stories founders tell because they are the stories that do not implicate the operating model.
An external shock and an internal weakness can both contribute to failure. Test how lower demand, higher input costs or delayed financing affect the model, rather than attributing a named company’s outcome to one unverified cause.
The one move that changes the odds today
You cannot out-market the five killers and you cannot out-raise them. You out-design them, from day one, by running the autopsy on yourself before an investor runs it on you.
Here is the move. Score your company out of five against the killers below, this week, with your leadership team in the room and no narrative allowed.
Use a recurring review to identify material risks while there is still time to change the plan. There is no validated eighteen-month warning period that applies across food biotech businesses.
Use the review on a regular schedule, with a named owner and a decision attached to each material risk. Its value is the opportunity to act earlier, not a guaranteed survival outcome.
One-minute brief
If you read no further, take this with you.
Five risks are worth checking together: weak market demand, unsustainable unit economics, operational failure, a funding shortfall and an inadequately planned regulatory pathway. They can compound. This is a proposed review structure, not a statistical ranking of causes of failure.
This issue gives you each killer with the mechanism that makes it lethal, the stage-adapted question that tells you who owns it in your company right now, and a worked example: a precision-fermentation founder weeks away from a custom plant, chasing fifteen interested brands, and what happened when we ran this test on him before he poured the foundation.
The point is not to admire the framework. The point is to find which killer is closest to your throat, and to act on it while it is still cheap.
The five killers
Risk one: weak market demand. Ask which customer problem the product resolves and what the buyer currently does instead. Polite feedback alone does not establish a market.
A product may be interesting without creating enough reason to change purchasing behaviour. Test the use case, price, availability and repeat demand. This does not establish that an entire product category lacks consumer need.
Risk two: unit economics. Determine which costs change with volume, utilisation and process performance. Increasing output can improve some costs and worsen others; calculate the effect for the actual operation.
Risk three: operational visibility. Track the indicators that reveal problems in quality, delivery, cost and cash. A monitoring system helps detect change; it does not guarantee a particular warning period.
Risk four: funding dependencies. Model what happens if the next financing takes longer, is smaller or does not arrive. Continuing external funding can be appropriate for R&D, but the dependency and contingency need to be explicit.
Risk five: regulatory planning. Identify the product, intended use, market, required evidence, owner and timeline early. A planned approval does not establish access, and permission does not by itself guarantee a competitive moat.
The same scorecard, at your stage
Pre-seed and seed. Score the company against all five, honestly, this week.
If several material risks remain unresolved, examine the hiring, financing and development plan before the next commitment. The number of red flags is not a validated rule for pausing a business.
Series A. Every one of the five killers must have a single named owner on the executive team.
If no one is accountable for the regulatory timeline or the downstream yield, the diligence is not thorough, it is structurally broken, and a competent investor will find that in an afternoon.
Growth. Killer two becomes the primary threat, because the plant is now the company.
Review construction pricing, scope changes, input-cost exposure and contingency with qualified project specialists. A fixed-price contract or hedge is not a universal requirement or a guarantee against dilution.
Related analysis: How ready is your food biotech business for its next stage?
Illustrative worked example
Illustrative scenario: a precision-fermentation team is considering a custom facility before it has tested whether sampling interest becomes paid demand.
He had fifteen brands who had requested samples and called it a pipeline. We ran the five-killer test in a room with no slides.
In this hypothetical case, the team postpones construction and tests paid demand through a suitable manufacturing partner. Of three interested prospects, one commits to a contract. That result changes the demand assumption; it is not a record of a client engagement or a survival prediction.
In this scenario, postponing the facility preserves the option to learn from the paid contract. It does not prove a survival rate or describe verified competitor liquidations.
The diagnostic question
Which of these five risks most affects your next milestone? Identify the evidence needed and the person responsible for obtaining it.
P.S.
Sources and scope
This is an edited adaptation of the author’s full Substack essay, first published 2026-05-21. Examples and editorial frameworks are distinguished from measured evidence. Source checks and editing: 16 October 2026.
Read the original Substack version. Read the FoodEdge editorial standards or suggest a correction.
Cover photograph: Photo by Headway / Unsplash. Context image, not a photograph of a company or experiment discussed here. Photo licence.
